Results 51 to 60 of about 7,402 (232)
Oncolytic Virotherapy Trials—Letter [PDF]
Clinical Cancer Research, 2013 We would like to thank Prof. Harrington for his insightful commentary ([1][1]) regarding our article by Kanerva and colleagues ([2][2]). During 2007–2011, the Advanced Therapy Access Program (ATAP) provided a unique opportunity for patients to access a technology they would not otherwise have ...
Akseli Hemminki +2 more
openaire +3 more sources
Molecular Therapy: Oncolytics, 2022 Oncolytic virotherapies have shown excellent promise in a variety of cancers by promoting antitumor immunity. However, the effects of oncolytic virus-mediated type I interferon (IFN-I) production on antitumor immunity remain unclear.
Nader El-Sayes +6 more
doaj
Asymptotic behavior of a doubly haptotactic cross-diffusion model for oncolytic virotherapy [PDF]
arXiv, 2021 This paper considers a model for oncolytic virotherapy given by the doubly haptotactic cross-diffusion system \begin{equation*} \left\{\begin{array}{ll} u_t=D_u\Delta u-\xi_u\nabla\cdot(u\nabla v)+\mu_u u(1-u)-\rho uz, v_t=- (\alpha_u u+\alpha_w w)v,\\ w_t=D_w\Delta w-\xi_w\nabla\cdot(w\nabla v)- w+\rho uz,\\ z_t=D_z\Delta z-\delta_z z- \rho uz ...
arxiv
Multiscale model for the effects of adaptive immunity suppression on the viral therapy of cancer [PDF]
, 2013 Oncolytic virotherapy - the use of viruses that specifically kill tumor cells - is an innovative and highly promising route for treating cancer. However, its therapeutic outcomes are mainly impaired by the host immune response to the viral infection.
arxiv +1 more source
Journal of Cellular and Molecular Medicine, Volume 29, Issue 11, June 2025.ABSTRACT A high death rate among glioma patients is primarily due to poor prognostic outcomes and tumour metastasis. Oncolytic viruses have gained attention as a potential therapeutic strategy as eliminating tumour cells and modifying tumour microenvironment.
Chunze Cui +3 more
wiley +1 more source
Enhancement of chemotherapy using oncolytic virotherapy: Mathematical and optimal control analysis [PDF]
Math. Biosci. Eng. 15 (2018), no. 6, 1435--1463, 2018 Oncolytic virotherapy (OV) has been emerging as a promising novel cancer treatment that may be further combined with the existing therapeutic modalities to enhance their effects. To investigate how OV could enhance chemotherapy, we propose an ODE based model describing the interactions between tumour cells, the immune response, and a treatment ...
arxiv +1 more source
Infection of non-cancer cells: A barrier or support for oncolytic virotherapy?
Molecular Therapy: Oncolytics, 2022 Oncolytic viruses are designed to specifically target cancer cells, sparing normal cells. Although numerous studies demonstrate the ability of oncolytic viruses to infect a wide range of non-tumor cells, the significance of this phenomenon for cancer ...
Victor A. Naumenko +4 more
doaj
Scientific Reports, 2021 Vaccination can prevent viral infections via virus-specific T cells, among other mechanisms. A goal of oncolytic virotherapy is replication of oncolytic viruses (OVs) in tumors, so pre-existing T cell immunity against an OV-encoded transgene would seem ...
Amanda W. K. AuYeung +8 more
doaj +1 more source
Targeting Triple‐Negative Breast Cancer: Resistance Mechanisms and Therapeutic Advancements
Cancer Medicine, Volume 14, Issue 9, May 2025.ABSTRACT Background Triple‐negative breast cancer (TNBC) is one of the most heterogeneous and menacing forms of breast cancer, with no sustainable cure available in the current treatment landscape. Its lack of targets makes it highly unresponsive to various treatment modalities, which is why chemotherapy continues to be the primary form of treatment ...
Rachana Raman +3 more
wiley +1 more source
Advancing ORFV‐Based Therapeutics to the Clinical Stage
Reviews in Medical Virology, Volume 35, Issue 3, May 2025.ABSTRACT The Orf virus (ORFV) is the prototype member of the parapoxvirus family and has long been recognized for its robust immunogenicity, favourable safety profile and its ability to stimulate both cellular and humoural immune responses without inducing significant anti‐vector immunity.
Matthias Helmold, Ralf Amann
wiley +1 more source